Dr. Gradishar Discusses the Treatment of HER2+ Breast Cancer

William J. Gradishar, MD
Published: Friday, Mar 30, 2018



William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of patients with HER2-positive breast cancer.

There are some patients who are not candidates for chemotherapy, or cannot tolerate it due to other medical comorbities, says Gradishar. Other options for these patients would be giving both hormonal therapy and HER2-targeted therapy simultaneously, such as lapatinib (Tykerb) and letrozole or anastrozole and trastuzumab (Herceptin).

More recently, dual targeting of HER2 along with an hormonal therapy has shown promise as a treatment for these patients. The phase III results from the ALTERNATIVE trial showed the median progression-free survival was 11 months (95% CI, 8.3-13.8) for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer assigned to lapatinib plus trastuzumab plus an aromatase inhibitor (AI) compared with 5.7 months (95% CI, 5.5-8.4) for patients assigned to trastuzumab plus an AI.

There has also been work looking at combining hormonal therapy with CDK 4/6 inhibitors and HER2-targeted therapy, Gradishar adds.
SELECTED
LANGUAGE


William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of patients with HER2-positive breast cancer.

There are some patients who are not candidates for chemotherapy, or cannot tolerate it due to other medical comorbities, says Gradishar. Other options for these patients would be giving both hormonal therapy and HER2-targeted therapy simultaneously, such as lapatinib (Tykerb) and letrozole or anastrozole and trastuzumab (Herceptin).

More recently, dual targeting of HER2 along with an hormonal therapy has shown promise as a treatment for these patients. The phase III results from the ALTERNATIVE trial showed the median progression-free survival was 11 months (95% CI, 8.3-13.8) for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer assigned to lapatinib plus trastuzumab plus an aromatase inhibitor (AI) compared with 5.7 months (95% CI, 5.5-8.4) for patients assigned to trastuzumab plus an AI.

There has also been work looking at combining hormonal therapy with CDK 4/6 inhibitors and HER2-targeted therapy, Gradishar adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x